Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from GlaxoSmithKline.

Oncology Briefings™: Assessing the Potential of BCMA as a Therapeutic Target in Multiple Myeloma

Release Date: November 13, 2020
Expiration Date: November 13, 2021

Activity Overview

This online activity is designed to provide a concise and focused overview of current and emerging therapies targeting B-cell maturation antigen (BCMA) for the treatment of patients with multiple myeloma (MM), the patient populations that might most benefit from these treatments, and the adverse events associated with these treatments and their management strategies. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward oncologists and hematologists involved in the treatment and management of multiple myeloma. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals (HCPs) involved in the management of patients with multiple myeloma will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the rationale for targeting BCMA as a potential treatment option for patients with multiple myeloma (MM)
• Discuss ongoing clinical trials evaluating investigational therapies that target BCMA for the treatment of patients with MM
• Identify patients for whom BCMA-targeting therapy would be most appropriate for the treatment of MM
• Outline a plan for monitoring and mitigating adverse events associated with the use of BCMA-targeting therapies

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Gareth Morgan, MBBCh, PhD, FRCP, FRCPath
Gareth Morgan, MBBCh, PhD, FRCP, FRCPath
Professor, Division of Medicine, NYU
Director, Myeloma Research
New York, NY

Disclosures: Consultant: GlaxoSmithKline, Bristol Myers Squibb and Janssen.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By